Boston Scientific Q4 revenue $4.56B (+22% YoY) beats guidance; adj EPS $0.70; FY25 organic guide 10-12%

BOSTON SCIENTIFIC CORP

2024-FY EPS reported $1.25 revenue$16,747,000,000

Q4 net sales $4.561B (+22.4% reported, 19.5% organic); GAAP EPS $0.38, adjusted EPS $0.70 vs guidance $0.64-0.66.
Full year 2024 net sales $16.747B (+17.6% reported); GAAP EPS $1.25, adjusted EPS $2.51.
Cardiovascular segment grew 28.8% reported; U.S. sales up 30.7%.
Guidance: Q1 2025 adj EPS $0.66-0.68, FY 2025 adj EPS $2.80-2.87; organic growth 10-12% for FY.
Completed acquisitions of Axonics and Cortex; announced deals for Bolt Medical and Intera Oncology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.